Sjogren’s syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Sjogren’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Sjogren’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sjogren’s syndrome: Overview
Sjogren’s syndrome is an autoimmune condition that can occur at any age, but is most common in older women. Many patients develop Sjogren’s syndrome as a complication of another autoimmune disease, such as rheumatoid arthritis or lupus. Symptoms vary in type and intensity, but many people with Sjogren’s are able to live normal lives.
Most of the treatment for Sjogren’s syndrome is aimed at relieving symptoms of dry eyes and mouth and preventing and treating long-term complications such as infection and dental disease. Treatments often do not completely eliminate the symptoms of dryness. Most patients with Sjogren’s syndrome remain healthy, but some rare complications have been described, including an increased risk for cancer of the lymph glands (lymphoma). Thus, regular medical care and follow up is important for all patients.
Report Highlights
This segment of the Sjogren’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sjogren’s syndrome Emerging Drugs
Further product details are provided in the report……..
Sjogren’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Sjogren’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Sjogren’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sjogren’s syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sjogren’s syndrome drugs.
Sjogren’s syndrome Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Sjogren’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Sjogren’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sjogren’s syndrome: Overview
Sjogren’s syndrome is an autoimmune condition that can occur at any age, but is most common in older women. Many patients develop Sjogren’s syndrome as a complication of another autoimmune disease, such as rheumatoid arthritis or lupus. Symptoms vary in type and intensity, but many people with Sjogren’s are able to live normal lives.
Most of the treatment for Sjogren’s syndrome is aimed at relieving symptoms of dry eyes and mouth and preventing and treating long-term complications such as infection and dental disease. Treatments often do not completely eliminate the symptoms of dryness. Most patients with Sjogren’s syndrome remain healthy, but some rare complications have been described, including an increased risk for cancer of the lymph glands (lymphoma). Thus, regular medical care and follow up is important for all patients.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sjogren’s syndrome R&D. The therapies under development are focused on novel approaches for Sjogren’s syndrome.
This segment of the Sjogren’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sjogren’s syndrome Emerging Drugs
- HZN-4920: Horizon Therapeutics
- Iscalimab: Novartis
Further product details are provided in the report……..
Sjogren’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Sjogren’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Sjogren’s syndrome
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Sjogren’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sjogren’s syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sjogren’s syndrome drugs.
Sjogren’s syndrome Report Insights
- Sjogren’s syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Sjogren’s syndrome drugs?
- How many Sjogren’s syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Sjogren’s syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sjogren’s syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sjogren’s syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Horizon Therapeutics
- Novartis
- Galapagos
- Sanofi
- Resolve Therapeutics
- Bristol-Myers Squibb
- Cytodyn
- MeiraGTx
- Alpine Immune Sciences
- Servier
- HZN-4920
- Iscalimab
- LOU-064
- GLPG3970
- SAR441344
- RSLV-132
- BMS-986325
- AAV-AQP1
- ALPN-303
- S95011
Introduction
Executive Summary
Sjogren’s syndrome: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
HZN-4920: Horizon Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BMS-986325: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
AAV-AQP1: MeiraGTx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sjogren’s syndrome Key Companies
Sjogren’s syndrome Key Products
Sjogren’s syndrome- Unmet Needs
Sjogren’s syndrome- Market Drivers and Barriers
Sjogren’s syndrome- Future Perspectives and Conclusion
Sjogren’s syndrome Analyst Views
Sjogren’s syndrome Key Companies
Appendix
Executive Summary
Sjogren’s syndrome: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
HZN-4920: Horizon Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BMS-986325: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
AAV-AQP1: MeiraGTx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sjogren’s syndrome Key Companies
Sjogren’s syndrome Key Products
Sjogren’s syndrome- Unmet Needs
Sjogren’s syndrome- Market Drivers and Barriers
Sjogren’s syndrome- Future Perspectives and Conclusion
Sjogren’s syndrome Analyst Views
Sjogren’s syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Sjogren’s syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Sjogren’s syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Sjogren’s syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Sjogren’s syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
